ArticleAdvanced drug delivery reviews2023
Light and drug delivery-based antimicrobial therapies in the fight against infectious diseases.
Tianhong Dai, Clive A Prestidge
Abstract readEditorial
In one paragraphArticle in Advanced drug delivery reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
2 authors.
Tianhong DaiWellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, United States. Electronic address: tdai@mgh.harvard.edu.
Clive A PrestidgeSchool of Pharmacy and Medical Science, University of South Australia, Australia. Electronic address: clive.prestidge@unisa.edu.au.
Funding
Antimicrobial blue light inactivation of pathogenic microbesR01AI123312 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG · 2016 to 2020
$2.6MCombination of Antimicrobial Blue Light and Antibiotics to Combat Multidrug-Resistant BacteriaR01AI177563 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Tianhong Dai, David C Hooper · 2024 to 2026
$2.1MAntimicrobial Blue Light for the Treatment of Otitis MediaR21DC021785 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG, SABHARWAL, VISHAKHA · 2025 to 2025
$490kDual-Wavelength Blue Light Irradiation for Improved Treatment of Staphylococcus aureus InfectionsR21AI178585 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG · 2023 to 2024
$459kAntimicrobial Blue Light Emitting Envelope for the Control of Cardiac Implantable Electronic Device InfectionsR21AI185539 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI DAI, TIANHONG, MELA, THEOFANIE · 2024 to 2025
$457kAntimicrobial blue light-activatable optical endotracheal tube to combat biofilms on the endotracheal tubeR21AI180632 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BERRA, LORENZO, DAI, TIANHONG · 2024 to 2025
$447kNIAID NIH HHS R01 AI123312NIAID NIH HHS R01 AI177563NIAID NIH HHS R21 AI178585NIAID NIH HHS R21 AI180632NIAID NIH HHS R21 AI185539NIDCD NIH HHS R21 DC021785
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Anti-Infective AgentsCommunicable DiseasesAnti-Bacterial AgentsDrug Delivery SystemsHumansAnti-Bacterial AgentsAnti-Infective Agents
Identifiers
PMID36948462
PMCPMC12866981
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390